An economic analysis performed in the UK has indicated that dabigatran etexilate is likely to be a cost-effective first-line treatment for the prevention of stroke and systemic embolism in patients with atrial fibrillation. For patients aged <80 years, incremental cost-effectiveness ratios for dabigatran were £4,831 per quality-adjusted life year (QALY) gained compared with warfarin and £3,457 per QALY gained compared with aspirin. In patients aged ≥80 years, the incremental cost-effectiveness ratio for dabigatran was £7,090 per QALY gained when compared with warfarin.
ORIGINAL RESEARCH PAPER
Kansal, A. R. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98, 573–578 (2012)
Rights and permissions
About this article
Cite this article
Dabigatran is a cost-effective first-line therapy in AF. Nat Rev Cardiol 9, 312 (2012). https://doi.org/10.1038/nrcardio.2012.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.48